Interim CFO McGauley buys 8,000 shares at $7.27 blended average; co-insider cluster buy pattern emerges at unprofitable biotech.
Thomas McGauley, Interim CFO of Tenax Therapeutics, executed 3 separate purchases totaling 8,000 shares for $58,164.00 on 2025-11-17 at prices ranging from $7.23 to $7.35. The buy-in brings his post-transaction holding to 5,000 shares from a negative pre-transaction position of -3,000 shares, suggesting a settlement or covering of a prior short/obligation. The 30-day price action shows +9.2% gains and 90-day performance of +21.2%, placing the current $7.32 price near recent highs at -6.5% from the 52-week high of $7.83. Most notably, 2 other insiders also purchased within the past 14 days, establishing a cluster buy pattern. However, the fundamental backdrop remains highly challenged: the company reported $0.00 revenue in the latest quarter and carries a net loss of $-15,804,000.00 with an unprofitable fiscal year, and the market cap stands at only $45,702,969.00. The clustering of insider purchases at a biotech with zero revenue and ongoing significant losses warrants scrutiny into the specific circumstances—whether this reflects a planned financing, clinical catalyst, or other material event.